FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*					V	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]										Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED					3. [3. Date of Earliest Transaction (Month/Day/Year) 05/07/2007										X Officer (give title Other (specify below) below) EVP, Medicines Dev. & CMO						
130 WAVERLY STREET				4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)										6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street)	IDGE M	ÍΑ	01239		_										y		led by More		rting Person One Report			
(City)	(S	tate)	(Zip)																			
			le I - No	1		_			cqu		Dis	<u>.</u>	-			y Owned			1.			
, , , , l c			2. Transaction Date (Month/Day/Ye		ar) E	2A. Deemed Execution Date, if any (Month/Day/Year)		. I	3. Transactio Code (Insti		4. Securit Disposed 5)					s ally following	Form:	: Direct · Indirect 6 str. 4)	7. Nature of Indirect Beneficial Ownership			
											v	Amount	(A) (D)	or F	Price	Reported Transact (Instr. 3 a	tion(s)			Instr. 4)		
Common Stock			05/0	5/07/2007					S ⁽¹⁾		32,500) D		\$30.59	102	,960		D				
Common Stock			05/0	05/07/2007					M		5,550	A	.	\$10.19	108	8,510		D				
Common Stock			05/0	5/07/2007					M		3,188	A		\$13.63	3 111	111,698		D				
Common Stock 05/07			7/200	/2007				M		7,626	7,626 A		\$13.11	119,324			D					
Common Stock															6,265		I 4		401(k)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transaction Code (Instr 8)				Exp	6. Date Exercis Expiration Dat (Month/Day/Ye			7. Title and Amount of Securities Underlying Derivative So (Instr. 3 and			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Dat Exe	te ercisabl		Expiration Date	Title	or Nu of	umber							
Stock Option	\$10.19	05/07/2007			M			5,550	12/	17/1998	(2)	09/16/2008	Commo	¹ 5	,550	\$0	0		D			
Stock Option	\$13.63	05/07/2007			M			3,188	03/	10/1999	(2)	12/09/2008	Commo	3	,188	\$0	0		D			
Stock Option	\$13.11	05/07/2007			M			7,626	03/	02/2000	(2)	12/01/2009	Commo	7	,626	\$0	0		D			

Explanation of Responses:

- $1.\ Transaction\ made\ pursuant\ to\ Dr.\ Alam's\ company\ approved\ trading\ plan\ established\ under\ Rule\ 10b5-1.$
- 2. Right to buy under 1996 Stock and Option Plan. Fully Vested

Remarks:

Kenneth S. Boger, Attorney-In-Fact

05/08/2007

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.